The estimated Net Worth of Anthony Digiandomenico is at least $25.6 Thousand dollars as of 2 May 2023. Mr. Digiandomenico owns over 83,333 units of ENDRA Life Sciences Inc stock worth over $25,609 and over the last 8 years he sold NDRA stock worth over $0. In addition, he makes $0 as Independent Director at ENDRA Life Sciences Inc.
Sign up
Mr. DiGiandomenico NDRA stock SEC Form 4 insiders trading
Anthony has made over 16 trades of the ENDRA Life Sciences Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 83,333 units of NDRA stock worth $100,000 on 2 May 2023.
The largest trade he's ever made was buying 83,333 units of ENDRA Life Sciences Inc stock on 2 May 2023 worth over $100,000. On average, Anthony trades about 7,093 units every 44 days since 2017. As of 2 May 2023 he still owns at least 102,434 units of ENDRA Life Sciences Inc stock.
You can see the complete history of Mr. Digiandomenico stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Anthony DiGiandomenico biography
Anthony DiGiandomenico serves as Independent Director of the Company. Mr. DiGiandomenico focuses on corporate finance and capital formation for growth-oriented companies. He has participated in all areas of corporate finance including private capital, public offerings, PIPEs, business consulting and strategic planning, and mergers and acquisitions. Mr. DiGiandomenico has also worked on a wide range of transactions for growth-oriented companies in biotechnology, nutritional supplements, manufacturing and entertainment industries. Prior to forming MDB Capital Group LLC in 1997, Mr. DiGiandomenico served as President and CEO of the Digian Company, a real estate development company. Mr. DiGiandomenico has also served on the board of directors of Cue Biopharma, Inc., an immunotherapy company, and currently serves on the board of directors of Provention Bio, Inc., a clinical-stage biopharmaceutical company. Mr. DiGiandomenico holds an MBA from the Haas School of Business at the University of California, Berkeley and a BS in Finance from the University of Colorado. Mr. DiGiandomenico’s financial expertise, general business acumen and significant executive leadership experience position him well to make valuable contributions to our Board of Directors.
How old is Anthony DiGiandomenico?
Anthony DiGiandomenico is 53, he's been the Independent Director of ENDRA Life Sciences Inc since 2013. There are 6 older and 4 younger executives at ENDRA Life Sciences Inc. The oldest executive at ENDRA Life Sciences Inc is Michael Harsh, 65, who is the Independent Director.
What's Anthony DiGiandomenico's mailing address?
Anthony's mailing address filed with the SEC is C/O ENDRA LIFE SCIENCES INC., 3600 GREEN COURT, SUITE 350, ANN ARBOR, MI, 48105.
Insiders trading at ENDRA Life Sciences Inc
Over the last 8 years, insiders at ENDRA Life Sciences Inc have traded over $893,199 worth of ENDRA Life Sciences Inc stock and bought 413,648 units worth $301,877 . The most active insiders traders include Group Ag Ubs, Capital Advisors, Llc Conra..., and Alexander Y Tokman. On average, ENDRA Life Sciences Inc executives and independent directors trade stock every 61 days with the average trade being worth of $5,922. The most recent stock trade was executed by Group Ag Ubs on 27 August 2024, trading 3,715 units of NDRA stock currently worth $2,043.
What does ENDRA Life Sciences Inc do?
endra life sciences is bringing new capabilities to ultrasound. our photo-acoustic solutions help medical researchers screen and modify disease models with unparalleled quality and speed. we’re proud to have a global installed base of leading institutions using our nexus-128 system, the only 3d imaging solution for imaging anatomy, physiology and labeled molecular targets. the nexus 128 is a preclinical photoacoustic computed tomography (ct) scanner for small animal imaging. the system is used for simple, fast, non-invasive quantification of physiological parameters such as tumor vasculature without ionizing radiation. the fully-3d imaging technology used by the nexus 128 provides increased sensitivity compared to slice-based scanners, and dynamic (4-d) photoacoustic ct scans allow for applications such as quantification of probe uptake. the nexus 128 is currently being used by top imaging laboratories around the globe.
What does ENDRA Life Sciences Inc's logo look like?
Complete history of Mr. Digiandomenico stock trades at ENDRA Life Sciences Inc, Cue Biopharma Inc, and Provention Bio
ENDRA Life Sciences Inc executives and stock owners
ENDRA Life Sciences Inc executives and other stock owners filed with the SEC include:
-
Francois Michelon,
Chairman of the Board, Chief Executive Officer -
Michael Thornton,
Chief Technology Officer -
David Wells,
Chief Financial Officer -
Michael Thornton,
Chief Technology Officer -
David R. Wells,
CFO & Sec. -
Joe Hassett,
Investors Relation -
Louis Basenese,
Independent Director -
Alexander Tokman,
Independent Director -
Michael Harsh,
Independent Director -
Sanjiv Gambhir,
Independent Director -
Anthony DiGiandomenico,
Independent Director -
Renaud Maloberti,
Chief Commercial Officer -
Steve Freeman,
HR Leader -
Dr. Jonathan Behr,
Co-Founder -
Capital Advisors, Llc Conra...,
-
Group Ag Ubs,
10% owner -
Lou Basenese,
Director -
Irina Pestrikova,
Senior Director, Finance